Mineralys prices $175M public offering (12.96M shares at $13.50); net proceeds ~$164.2M

Mineralys Therapeutics, Inc.

Offering of 12,962,962 shares at $13.50; gross proceeds $175M; net proceeds ~$164.2M.
Underwriters have 30-day option for additional 1,944,444 shares, adding up to $26.3M.
Proceeds to fund lorundrostat clinical development, R&D, manufacturing, and pre-commercialization.
Joint book-runners: BofA Securities, Evercore ISI, Goldman Sachs, Stifel, Wells Fargo.
Expected to close March 13, 2025; subject to customary conditions.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.